Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Caliper Selects BIND Technology from SRU Biosystems

By Drug Discovery Trends Editor | February 5, 2010

Caliper Life Sciences, (Hopkinton, Mass.) will begin using SRU Biosystems’ label-free BIND technology to offer new functional assays as part of its Discovery Alliances and Services.

BIND technology, developed by SRU Biosystems, Woburn, Mass., provides researchers with an ultra-high throughput screening and profiling system for cell-based and biochemical assays. BIND technology for cell-based assays offers an orthogonal screening tool to access new hits and lead molecules that are not detected by other systems, including compounds that undergo G-protein switching, non-G protein coupled pathways, inverse and partial agonists, and receptor desensitization.

The screening platform is robust and can be applied to both over-expressed and endogenous receptors, and can be used with low numbers of primary cells. The technology can also used for receptor profiling on native cells, due to the high sensitivity of the response. Lastly, the technology provides a way to easily screen Gi-coupled GPCR targets and ion channels, which have been traditionally difficult to assess.

“Caliper Life Sciences … is uniquely positioned to offer BIND technology as a contract service to the biotechnology and pharmaceutical communities. They have tremendous knowledge utilizing innovative technologies to advance drug discovery and will provide an outstanding new service to the drug discovery industry,” said Rick Wagner, PhD, President and CEO of SRU Biosystems.

SRU Biosystems’ label-free BIND technology can be used for complex cellular assays such as GPCR pathway analysis, ion channel assays and cell adhesion assays; as well as biochemical assays, such as protein-protein binding, enzyme assays, and fragment and small molecule screening. These applications have been utilized in exploring assay development, 1536-well high throughput screening, and lead profiling.

SRU anticipates a continued expansion of its label-free BIND products, creating new assay capabilities.

Date: February 1, 2010
Source: SRU Biosystems

This news was published in Drug Discovery & Development magazine: Vol. 13, No. 1, January/February, 2010, p. 14.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50